Tadalafil Alleviates Muscle Ischemia in Patients with Becker Muscular Dystrophy
- 28 November 2012
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 4 (162) , 162ra155
Abstract
Becker muscular dystrophy (BMD) is a progressive X-linked muscle wasting disease for which there is no treatment. Like Duchenne muscular dystrophy (DMD), BMD is caused by mutations in the gene encoding dystrophin, a structural cytoskeletal protein that also targets other proteins to the muscle sarcolemma. Among these is neuronal nitric oxide synthase (nNOSμ), which requires certain spectrin-like repeats in dystrophin’s rod domain and the adaptor protein α-syntrophin to be targeted to the sarcolemma. When healthy skeletal muscle is subjected to exercise, sarcolemmal nNOSμ-derived NO attenuates local α-adrenergic vasoconstriction, thereby optimizing perfusion of muscle. We found previously that this protective mechanism is defective—causing functional muscle ischemia—in dystrophin-deficient muscles of the mdx mouse (a model of DMD) and of children with DMD, in whom nNOSμ is mislocalized to the cytosol instead of the sarcolemma. We report that this protective mechanism also is defective in men with BMD in whom the most common dystrophin mutations disrupt sarcolemmal targeting of nNOSμ. In these men, the vasoconstrictor response, measured as a decrease in muscle oxygenation, to reflex sympathetic activation is not appropriately attenuated during exercise of the dystrophic muscles. In a randomized placebo-controlled crossover trial, we show that functional muscle ischemia is alleviated and normal blood flow regulation is fully restored in the muscles of men with BMD by boosting NO-cGMP (guanosine 3′,5′-monophosphate) signaling with a single dose of the drug tadalafil, a phosphodiesterase 5A inhibitor. These results further support an essential role for sarcolemmal nNOSμ in the normal modulation of sympathetic vasoconstriction in exercising human skeletal muscle and implicate the NO-cGMP pathway as a putative new target for treating BMD.Keywords
This publication has 60 references indexed in Scilit:
- Drug screening in a zebrafish model of Duchenne muscular dystrophyProceedings of the National Academy of Sciences, 2011
- Golgi and sarcolemmal neuronal NOS differentially regulate contraction-induced fatigue and vasoconstriction in exercising mouse skeletal muscleJournal of Clinical Investigation, 2010
- Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary careThe Lancet Neurology, 2010
- Nitric oxide release combined with nonsteroidal antiinflammatory activity prevents muscular dystrophy pathology and enhances stem cell therapyProceedings of the National Academy of Sciences, 2007
- Function and Genetics of Dystrophin and Dystrophin-Related Proteins in MusclePhysiological Reviews, 2002
- Nitric oxide‐dependent modulation of sympathetic neural control of oxygenation in exercising human skeletal muscleThe Journal of Physiology, 2002
- The muscular dystrophiesThe Lancet, 2002
- Impaired Modulation of Sympathetic Vasoconstriction in Contracting Skeletal Muscle of Rats With Chronic Myocardial InfarctionsCirculation Research, 2001
- Nitric oxide mediates contraction‐induced attenuation of sympathetic vasoconstriction in rat skeletal muscleThe Journal of Physiology, 1998
- THE MOLECULAR-BASIS FOR DUCHENNE VERSUS BECKER MUSCULAR-DYSTROPHY - CORRELATION OF SEVERITY WITH TYPE OF DELETION1989